ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS
The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 01. Nov. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
LEE YOON-SUK [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-11-01, Last update posted on www.tib.eu: 2024-03-14, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
EP4061817 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000119229 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000119229 | ||
| 003 | DE-627 | ||
| 005 | 20240322140647.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000119229 | ||
| 035 | |a (EPA)EP4061817 | ||
| 035 | |a (EPA)75980093 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a LEE YOON-SUK |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a ADENOSINE RECEPTOR ANTAGONIST COMPOUNDS |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-11-01, Last update posted on www.tib.eu: 2024-03-14, Last updated: 2024-03-22 | ||
| 520 | |a The present disclosure provides adenosine receptor (e.g., A2A and/or A1 receptor) antagonist compounds and compositions including said compounds. The present disclosure also provides methods of using said compounds and compositions for modulating (e.g., inhibiting or antagonizing) A2A and/or A1 receptor in a biological system. The compounds and compositions find use in various therapeutic applications including the treatment of cancer and in immuno-oncology. The compounds and compositions find use in various therapeutic applications including the treatment of central nervous system or neurodegenerative diseases, such as Parkinson’s disease. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a KWON SUNG-WOOK |4 aut | |
| 700 | 0 | |a KIM KYUNG-SUN |4 aut | |
| 700 | 0 | |a KIM JEONG-GEUN |4 aut | |
| 700 | 0 | |a KIM JEONG-AH |4 aut | |
| 700 | 0 | |a MOON AN-NA |4 aut | |
| 700 | 0 | |a PARK SUN-YOUNG |4 aut | |
| 700 | 0 | |a BAN JUN-SU |4 aut | |
| 700 | 0 | |a SONG DONG-KEUN |4 aut | |
| 700 | 0 | |a JUNG JU-YOUNG |4 aut | |
| 700 | 0 | |a LEE SOO-JIN |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 01. Nov. |
| 773 | 1 | 8 | |g year:2023 |g day:01 |g month:11 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/75980093/publication/EP4061817A1?q=EP4061817 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 01 |c 11 | ||